June 20, 2023 12:55 PM EDT

MarketingRx roundup: Eli Lilly’s marketing chief at Cannes Lions, Biogen raises more Alzheimer’s awareness

Beth Snyder Bulik

Senior Editor

Eli Lilly’s chief corporate brand officer, Lina Polemini, joined two other marketing leaders at Cannes Lions on Monday to talk about what it means to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

MarketingRx roundup: Eli Lilly’s marketing chief at Cannes Lions, Biogen raises more Alzheimer’s awareness

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Sofinnova outlines $550M fund after IPOs and M&A deals

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Mar­ket­ingRx roundup: Eli Lil­ly’s mar­ket­ing chief at Cannes Li­ons, Bio­gen rais­es more Alzheimer’s aware­ness

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

MarketingRx roundup: Eli Lilly’s marketing chief at Cannes Lions, Biogen raises more Alzheimer’s awareness

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Sofinnova outlines $550M fund after IPOs and M&A deals

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients